165 related articles for article (PubMed ID: 18955788)
21. Impact of chromosome 13 deletion and plasma cell load on long-term survival of patients with multiple myeloma undergoing autologous transplantation.
Paul E; Sutlu T; Deneberg S; Alici E; Björkstrand B; Jansson M; Lerner R; Wallblom A; Gahrton G; Nahi H
Oncol Rep; 2009 Jul; 22(1):137-42. PubMed ID: 19513515
[TBL] [Abstract][Full Text] [Related]
22. Results of a retrospective single institution analysis of targeted skeletal radiotherapy with (166)Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomes.
Christoforidou AV; Saliba RM; Williams P; Qazilbash M; Roden L; Aleman A; Weber D; Mendoza F; Podoloff D; Wendt R; Breitz H; Alexanian R; Champlin R; Giralt S
Biol Blood Marrow Transplant; 2007 May; 13(5):543-9. PubMed ID: 17448913
[TBL] [Abstract][Full Text] [Related]
23. Simple variables predict survival after autologous transplantation: a single centre experience in 181 multiple myeloma patients.
Krejci M; Hajek R; Buchler T; Krivanova A; Svobodnik A; Pour L; Adam Z; Mayer J; Vorlicek J
Neoplasma; 2007; 54(2):143-8. PubMed ID: 17319788
[TBL] [Abstract][Full Text] [Related]
24. Impact of Dose-Adjusted Melphalan in Obese Patients Undergoing Autologous Stem Cell Transplantation.
Shultes KC; Arp C; Stockerl-Goldstein K; Trinkaus K; DeFrates S
Biol Blood Marrow Transplant; 2018 Apr; 24(4):687-693. PubMed ID: 29225163
[TBL] [Abstract][Full Text] [Related]
25. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
[TBL] [Abstract][Full Text] [Related]
26. Induction therapy pre-autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation.
Hwa YL; Kumar SK; Gertz MA; Lacy MQ; Buadi FK; Kourelis TV; Gonsalves WI; Rajkumar SV; Go RS; Leung N; Kapoor P; Dingli D; Kyle RA; Russell S; Lust JA; Hayman SR; Lin Y; Zeldenrust S; Dispenzieri A
Am J Hematol; 2016 Oct; 91(10):984-8. PubMed ID: 27341539
[TBL] [Abstract][Full Text] [Related]
27. Clinical significance of the appearance of abnormal protein band in patients with multiple myeloma.
Jo JC; Yoon DH; Kim S; Lee K; Kang EH; Jang S; Park CJ; Chi HS; Huh J; Park CS; Suh C
Ann Hematol; 2014 Mar; 93(3):463-9. PubMed ID: 23999647
[TBL] [Abstract][Full Text] [Related]
28. [High-dose chemotherapy and autologous stem cell transplantation in multiple myeloma patients--single center experience].
Piatkowska-Jakubas B; Wolska-Smoleń T; Mensah-Glanowska P; Hawrylecka D; Szostek M; Walter Z; Skotnicki AB
Przegl Lek; 2011; 68(2):78-81. PubMed ID: 21751514
[TBL] [Abstract][Full Text] [Related]
29. Combined submyeloablative and myeloablative dose intense melphalan results in satisfactory responses with acceptable toxicity in patients with multiple myeloma.
Novitzky N; Thomson J; Thomas V; du Toit C; Mohamed Z; McDonald A
Biol Blood Marrow Transplant; 2010 Oct; 16(10):1402-10. PubMed ID: 20385248
[TBL] [Abstract][Full Text] [Related]
30. Prognostic relevance of CD56 expression in multiple myeloma: a study including 107 cases treated with high-dose melphalan-based chemotherapy and autologous stem cell transplant.
Chang H; Samiee S; Yi QL
Leuk Lymphoma; 2006 Jan; 47(1):43-7. PubMed ID: 16321826
[TBL] [Abstract][Full Text] [Related]
31. High-Dose Melphalan Plus Thiotepa as Conditioning Regimen before Second Autologous Stem Cell Transplantation for "De Novo" Multiple Myeloma Patients: A Phase II Study.
Musso M; Messina G; Marcacci G; Crescimanno A; Console G; Donnarumma D; Scalone R; Pinto A; Martino M
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1932-8. PubMed ID: 26099830
[TBL] [Abstract][Full Text] [Related]
32. Outcome of patients with IgD and IgM multiple myeloma undergoing autologous hematopoietic stem cell transplantation: a retrospective CIBMTR study.
Reece DE; Vesole DH; Shrestha S; Zhang MJ; Pérez WS; Dispenzieri A; Milone GA; Abidi M; Atkins H; Bashey A; Bredeson CN; Boza WB; Freytes CO; Gale RP; Gajewski JL; Gibson J; Hale GA; Kumar S; Kyle RA; Lazarus HM; McCarthy PL; Pavlovsky S; Roy V; Weisdorf DJ; Wiernik PH; Hari PN
Clin Lymphoma Myeloma Leuk; 2010 Dec; 10(6):458-63. PubMed ID: 21156462
[TBL] [Abstract][Full Text] [Related]
33. Usefulness and safety of oral cryotherapy in the prevention of oral mucositis after conditioning regimens with high-dose melphalan for autologous stem cell transplantation for lymphoma and myeloma.
Batlle M; Morgades M; Vives S; Ferrà C; Oriol A; Sancho JM; Xicoy B; Moreno M; Magallón L; Ribera JM
Eur J Haematol; 2014 Dec; 93(6):487-91. PubMed ID: 24889275
[TBL] [Abstract][Full Text] [Related]
34. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure.
Spencer A; Prince HM; Roberts AW; Prosser IW; Bradstock KF; Coyle L; Gill DS; Horvath N; Reynolds J; Kennedy N
J Clin Oncol; 2009 Apr; 27(11):1788-93. PubMed ID: 19273705
[TBL] [Abstract][Full Text] [Related]
35. Prognostic value of sequencing-based minimal residual disease detection in patients with multiple myeloma who underwent autologous stem-cell transplantation.
Takamatsu H; Takezako N; Zheng J; Moorhead M; Carlton VEH; Kong KA; Murata R; Ito S; Miyamoto T; Yokoyama K; Matsue K; Sato T; Kurokawa T; Yagi H; Terasaki Y; Ohata K; Matsumoto M; Yoshida T; Faham M; Nakao S
Ann Oncol; 2017 Oct; 28(10):2503-2510. PubMed ID: 28945825
[TBL] [Abstract][Full Text] [Related]
36. High-dose chemotherapy with autologous stem cell transplantation for multiple myeloma: what predicts the outcome? Experience from a developing country.
Kumar L; Ghosh J; Ganessan P; Gupta A; Hariprasad R; Kochupillai V
Bone Marrow Transplant; 2009 Mar; 43(6):481-9. PubMed ID: 18978818
[TBL] [Abstract][Full Text] [Related]
37. Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma.
Cavo M; Di Raimondo F; Zamagni E; Patriarca F; Tacchetti P; Casulli AF; Volpe S; Perrone G; Ledda A; Ceccolini M; Califano C; Bigazzi C; Offidani M; Stefani P; Ballerini F; Fiacchini M; de Vivo A; Brioli A; Tosi P; Baccarani M
J Clin Oncol; 2009 Oct; 27(30):5001-7. PubMed ID: 19720903
[TBL] [Abstract][Full Text] [Related]
38. Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model.
Grazziutti ML; Dong L; Miceli MH; Krishna SG; Kiwan E; Syed N; Fassas A; van Rhee F; Klaus H; Barlogie B; Anaissie EJ
Bone Marrow Transplant; 2006 Oct; 38(7):501-6. PubMed ID: 16980998
[TBL] [Abstract][Full Text] [Related]
39. Intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: a matched comparison to a melphalan-only approach.
Blanes M; Lahuerta JJ; González JD; Ribas P; Solano C; Alegre A; Bladé J; San Miguel JF; Sanz MA; de la Rubia J
Biol Blood Marrow Transplant; 2013 Jan; 19(1):69-74. PubMed ID: 22897964
[TBL] [Abstract][Full Text] [Related]
40. Autologous stem-cell transplantation in patients with multiple myeloma.
Stojanoski Z; Georgievski B; Cevreska L; Stojanovic A; Pivkova A; Genadieva-Stavric S; Stankovic S; Karadzova-Stojanoska A
Prilozi; 2008 Jul; 29(1):265-79. PubMed ID: 18709015
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]